Salarius Pharmaceuticals重新遵守纳斯达克最低出价要求

2025-09-09 20:09

Salarius Pharmaceuticals (NASDAQ:SLRX) on Tuesday said it has received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement.
As disclosed on August 27, Salarius has until October 20, 2025 to regain compliance with the listing rule.
On January 13, 2025, Salarius announced it had entered into a definitive merger agreement for a business combination with Decoy Therapeutics. Under the agreement, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics.
SLRX +7.52% premarket to $5.0.
Source: Press Release

More on Salarius Pharmaceuticals